• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
https://www.onescdvoice.com/wp-content/uploads/2019/11/gray-blood-test-1_custom-0dda4448ed33228227001e60440bddf49a35772e-s1500-c85.jpg
clinical trials and research

Gene-Edited 'Supercells' Make Progress In Fight Against Sickle Cell Disease

Doctors are reporting the first evidence that genetically edited cells could offer a safe way to treat sickle cell disease, a devastating, incurable disorder that afflicts millions of people around the world.

Billions of cells that were genetically modified with the powerful gene-editing technique called CRISPR have started working, as doctors had hoped, inside the body of the first sickle cell patient to receive the experimental treatment, according to highly anticipated data released Tuesday.

The edited cells are producing a crucial protein at levels that have already exceeded what doctors thought would be needed to alleviate the excruciating, life-threatening complications of the genetic blood disorder, the early data show. Moreover, the cells appear to have already started to spare the patient from the agonizing attacks of pain that are the hallmark of the disorder.

"We are very, very excited," says Dr. Haydar Frangoul of the Sarah Cannon Research Institute in Nashville, Tenn., who is treating the patient. "This preliminary data shows for the first time that gene editing has actually helped a patient with sickle cell disease. This is definitely a huge deal."

Nov 19, 2019
https://www.onescdvoice.com/wp-content/uploads/2019/11/us-food-and-drug-administration-fda-logo-vector.png
business

FDA Approves First Targeted Therapy to Treat Patients with Painful Complication of Sickle Cell Disease

Today, the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for patients age 16 years and older.

“Hope has never been higher for people living with sickle cell disease and their families and supporters, with a pipeline of new treatments on the horizon, like the one being approved today, and several initiatives underway to better utilize current tools in the battle against the painful and deadly blood disorder,” said Acting FDA Commissioner Adm. Brett P. Giroir, M.D. “The opportunity before us in the coming months and years is profound and historic.”

Nov 15, 2019